Perseus SENOLYTIX

Perseus Proteomics is a Japanese biotechnology company specializing in the discovery and development of therapeutic monoclonal antibodies for oncology and other unmet medical needs. Leveraging its proprietary high-throughput antibody screening technologies, the company focuses on targeting specific cell-surface proteins involved in cancer progression. Its lead clinical candidate, PPMX-T003, is an antibody targeting the transferrin receptor for the treatment of hematologic malignancies. Perseus Proteomics also develops antibody-drug conjugates and radioimmunotherapies to provide more effective treatment options for refractory cancers.